Roche to file MS drug for approval in early 2016; Bristol-Myers' Opdivo scores Early Access spot in U.K.; Boehringer diabetes med falls short in Phase II;

> Roche ($RHHBY) touted success for its MS drug ocrelizumab in two late-stage studies, saying the data puts it on track for regulatory filings in early 2016. Report

> Bristol-Myers Squibb's ($BMY) new cancer immuno-therapy Opdivo scored a spot on the U.K.'s Early Access to Medicines Scheme, the first lung cancer drug to be approved under the program. Report

> Boehringer Ingelheim and its development partner Vitae ($VTAE) saw their diabetes drug VTP-34072 fail to significantly decrease blood sugar in a mid-stage trial. Report

> AstraZeneca's ($AZN) Crestor patent was invalidated by the Brazilian federal courts. Report

> Novartis' ($NVS) eye care unit Alcon won European approval for a new type of lens used in cataract surgery. Release

> Cosmederm Bioscience expanded its itch-relief product line TriClam with two new topical products. Release

And Finally... WPP-owned brand agency The Partners appointed Peter Henshaw from Inventiv Europe as a creative director for its health team. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.